Andere Sprachen Foghorn Therapeutics Inc.

Aktien

A2QFQD

US3441741077

FHTX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 02.07.2024			% 5 Tage	% 1. Jan.
5,44 ^USD	-6,85 %		+2,26 %	-15,66 %

20.05.	Foghorn Therapeutics preist 110 Millionen Dollar für Aktien und vorfinanzierte Optionsscheine	MT
06.05.	Foghorn Therapeutics Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer	13.06.
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June	28.05.
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline	23.05.
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline	23.05.
Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants	20.05.
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants	20.05.
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06.05.
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update	06.05.
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update	06.05.
North American Morning Briefing : Stock Futures -2-	06.05.
Foghorn Therapeutics Names Kristian Humer CFO	16.04.
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer	16.04.
Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	16.04.
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs	09.04.
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09.04.
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference	05.04.
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting	26.03.
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07.03.
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Foghorn Therapeutics Inc.

Aktien

A2QFQD

US3441741077

FHTX

Andere Sprachen

Filter